 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...2425262728293031323334...208209» |
- |||||| Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Sep 4, 2025
P3, N=600, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting
- | Clinical, Retrospective data, Review, Journal: What is the optimal first-line regimen for patients with advanced HER2-positive breast cancer: A systematic review and network meta-analysis. (Pubmed Central) - Sep 4, 2025
Not yet recruiting --> Recruiting The THPyr regimen might be optimal as initial treatment for patients with advanced HER2-positive BC and is likely to be approved as a new first-line treatment option.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker: Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy. (Pubmed Central) - Sep 4, 2025
The TyG index is a reliable long-term predictor of response to combined immunotherapy and targeted therapy in patients with HBV-related HCC. Patients with a low TyG index tend to experience better clinical outcomes.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group, sorafenib / Generic mfg.
Review, Journal: The synergistic potential of camrelizumab and rivoceranib in advanced hepatocellular carcinoma: a review of current evidence. (Pubmed Central) - Sep 4, 2025
Patients with a low TyG index tend to experience better clinical outcomes. The final analysis of CARES-310 demonstrated a median overall survival (OS) of 23.8
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Efficacy and Safety of Camrelizumab Plus Apatinib for Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. (Pubmed Central) - Sep 4, 2025
Camrelizumab plus apatinib has shown promising efficacy with improved OS, PFS, and response rates. Large-scale trials are warranted to validate these findings and optimize treatment strategies.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer. (Pubmed Central) - Sep 4, 2025
DEB-TACE combined with trans arterial infusion of carrelizumab is safe and effective in the treatment of advanced liver cancer. Compared with DEB-TACE alone, this combination therapy results in higher CD3+, CD4+, and CD4+/CD8+ levels, as well as reduced CD8+, AFP, and PIVKA-II levels.
- || remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU (clinicaltrials.gov) - Sep 4, 2025
P1/2, N=24, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Compared with DEB-TACE alone, this combination therapy results in higher CD3+, CD4+, and CD4+/CD8+ levels, as well as reduced CD8+, AFP, and PIVKA-II levels. Recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2025 | Trial primary completion date: Nov 2023 --> Mar 2025
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Evolving strategies in the management of non-small cell lung cancer brain metastases: insights from the C-Brain trial. (Pubmed Central) - Sep 4, 2025
Recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2025 | Trial primary completion date: Nov 2023 --> Mar 2025 No abstract available
- | AiRuiKa (camrelizumab) / HLB Bio Group, Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Checkpoint inhibition: Myasthenia Gravis-Like Symptoms Following Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma: A Case Report. (Pubmed Central) - Sep 4, 2025
No abstract available At 12
- || Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Review, Journal: All eyes on semifluorinated alkanes: a comprehensive review of the influence of semifluorinated alkane eyedrops on tear film stabilization and drug delivery in dry eye disease. (Pubmed Central) - Sep 4, 2025
At 12 Clinical evidence demonstrates that PFBP-based CsA eyedrops (VEVYE
- ||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
Enrollment closed, Enrollment change, Trial primary completion date: Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (clinicaltrials.gov) - Sep 4, 2025
P2, N=153, Active, not recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical evidence demonstrates that PFBP-based CsA eyedrops (VEVYE Recruiting --> Active, not recruiting | N=240 --> 153 | Trial primary completion date: Jun 2025 --> Dec 2025
- ||| HRS-9821 / GSK
Enrollment open: A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. (clinicaltrials.gov) - Sep 3, 2025
P1, N=82, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Recruiting --> Active, not recruiting | N=240 --> 153 | Trial primary completion date: Jun 2025 --> Dec 2025 Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 29, 2025
P1/2, N=142, Completed, Sponsor: Xinrui Zhu?MD
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Safety and Efficacy of Camrelizumab Combined With Apatinib for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis (Exhibit Hall) - Aug 29, 2025 - Abstract #ACG2025ACG_2580;
564 patients from 14 studies were included in the analysis. The pooled 1-year overall survival (OS) from 8 studies was 61% (95% CI: 45
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Efficacy and Safety of Camrelizumab Plus Apatinib for Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis (Exhibit Hall) - Aug 29, 2025 - Abstract #ACG2025ACG_1222;
The pooled 1-year overall survival (OS) from 8 studies was 61% (95% CI: 45 The pooled 1-year overall survival (OS) from 6 studies was 71% (95% CI: 50
- || HR091506 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change: A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy Subjects (clinicaltrials.gov) - Aug 28, 2025
P1, N=36, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
The pooled 1-year overall survival (OS) from 6 studies was 71% (95% CI: 50 Not yet recruiting --> Completed | N=18 --> 36
- |||| zeprumetostat (SHR-2554) / Treeline Biosci
Enrollment open: Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 28, 2025
P2, N=351, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Completed | N=18 --> 36 Not yet recruiting --> Recruiting
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal, HEOR, Cost-effectiveness: Herombopag Versus rhTPO in Stem Cell Transplantation: A Comparative Study of Efficacy, Safety, and Cost-Effectiveness. (Pubmed Central) - Aug 28, 2025
Its demonstrated benefits in accelerating platelet recovery, reducing hemorrhagic complications, and lowering healthcare costs suggest it should be considered as a preferred therapeutic option, especially for allo-PBSCT recipients. These findings have important implications for optimizing supportive care in hematopoietic stem cell transplantation.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, Journal: Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory. (Pubmed Central) - Aug 28, 2025
These findings have important implications for optimizing supportive care in hematopoietic stem cell transplantation. This TRIPLET protocol has significant safety and effectiveness in the management of patients with HCC refractory to TACE.
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: CASTLE-ZS-03: Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. (clinicaltrials.gov) - Aug 28, 2025
P2, N=36, Not yet recruiting, Sponsor: Fudan University
- ||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial completion: A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation (clinicaltrials.gov) - Aug 28, 2025
P2, N=60, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This TRIPLET protocol has significant safety and effectiveness in the management of patients with HCC refractory to TACE. Unknown status --> Completed
- | New trial: HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov) - Aug 28, 2025
P=N/A, N=150, Not yet recruiting, Sponsor: Fudan University
- |||| Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Trial completion: A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine (clinicaltrials.gov) - Aug 27, 2025
P4, N=204, Completed, Sponsor: Novaliq GmbH
Unknown status --> Completed Active, not recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer (clinicaltrials.gov) - Aug 27, 2025
P2, N=120, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Retrospective data, Journal: Efficacy and safety of antibody drug conjugate therapy in patients with human epidermal growth factor receptor 2-positive non-small cell lung cancer: A single-arm systematic review and meta-analysis. (Pubmed Central) - Aug 27, 2025
Notably, T-DXd demonstrated the highest level of antitumor activity. In conclusion, the results of the present study may assist clinicians in selecting the optimal therapeutic option for the treatment of NSCLC.
- ||| HRS-4642 / Jiangsu Hengrui Pharma
Enrollment change: HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov) - Aug 26, 2025
P2, N=30, Recruiting, Sponsor: Ruijin Hospital
In conclusion, the results of the present study may assist clinicians in selecting the optimal therapeutic option for the treatment of NSCLC. N=60 --> 30
- |||||| GSK5784283 / GSK
Enrollment open: A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma (clinicaltrials.gov) - Aug 26, 2025
P3, N=408, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
N=60 --> 30 Not yet recruiting --> Recruiting
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy (clinicaltrials.gov) - Aug 26, 2025
P2, N=32, Recruiting, Sponsor: Tang-Du Hospital
- | Hetronifly (serplulimab) / Alvogen, Shanghai Henlius Biotech, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1/2 trial: An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing (clinicaltrials.gov) - Aug 26, 2025
P1/2, N=100, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment change, Trial withdrawal: Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov) - Aug 26, 2025
P=N/A, N=0, Withdrawn, Sponsor: Hebei Medical University Fourth Hospital
Not yet recruiting --> Recruiting N=30 --> 0 | Not yet recruiting --> Withdrawn
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal: Mechanism-based perspective on metal ion-induced signal instability and development of a robust LC-MS/MS method for trace quantification of hetrombopag in plasma. (Pubmed Central) - Aug 26, 2025
The method was applied to determine the plasma concentration of hetrombopag in eight male beagle dogs after each administration of three 2.5?mg hetrombopag tablets. The analytical methodology described in the present work should be useful in the future work aiming to establish a model relating metal-sensitive other compounds.
- || AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
P2 data, Journal: Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. (Pubmed Central) - Aug 26, 2025
The analytical methodology described in the present work should be useful in the future work aiming to establish a model relating metal-sensitive other compounds. Camrelizumab plus famitinib improved antitumor activity while exhibiting a manageable safety profile in patients with pretreated R/M CC, potentially offering a novel treatment option.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Clinical data, Journal, Real-world evidence: Real world clinical data analysis of fuzuloparib for the treatment of ovarian epithelial cancer patients (Pubmed Central) - Aug 26, 2025
The effectiveness of fuzuloparib in clinical application is generally consistent with other drugs in the same class, with good safety. This study provids new clinical evidence for the treatment of ovarian cancer with fuzuloparib.
- | Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health, cyclosporine ophthalmic emulsion / Generic mfg.
Retrospective data, Journal: Assessment the Safety of CyclASol compared with Vehicle and Commercially Available 0.05% Cyclosporine in Dry Eye Disease: A Systematic Review and Meta-analysis. (Pubmed Central) - Aug 26, 2025
Based on the data presented in the meta-analysis, CyclASol is a safe treatment for patients with DED. However, the comparable likelihood of experiencing TEAEs and ocular TEAEs between CyclASol and 0.05% CsA suggests that there is not sufficient evidence to indicate a superior safety profile of CyclASol over commercially available CsA.
- || Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
PK/PD data, Journal: Physiologically-Based Pharmacokinetics and Empirical Pharmacodynamic Modeling for Pediatric Henagliflozin Dosing: Clinical Insights for Chinese Patients. (Pubmed Central) - Aug 26, 2025
The verified PBPK and empirical PD models informed dosing recommendations in pediatric populations aged 1 month to 18 years, achieving henagliflozin exposures comparable to those in adult patients receiving a 5-10?mg dose. This study shows that PBPK and PD modeling effectively guide pediatric dosing of henagliflozin, reducing trial reliance and supporting real-world validation.
- | Epidaza (chidamide) / Chipscreen, Itari (linperlisib) / Shanghai YingLi Pharma
New P1/2 trial: Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov) - Aug 26, 2025
P1/2, N=54, Not yet recruiting, Sponsor: Sun Yat-sen University
- |||| HRS-4508 / Jiangsu Hengrui Pharma
New P1/2 trial: A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor (clinicaltrials.gov) - Aug 26, 2025
P1/2, N=120, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Targeting tumor vascular endothelial cells for hepatocellular carcinoma treatment. (Pubmed Central) - Aug 26, 2025
Recently, Wu et al reported that apatinib, an inhibitor of vascular endothelial growth factor receptor 2, can inhibit tumor VEC glycolysis by regulating phosphatidylinositol 3-kinase/protein kinase B/6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 signaling pathway to suppress HCC progression. With great interest, this editorial paper aims to review the function and key molecular signaling pathways of tumor VECs in HCC initiation and progression and summarize potential treatment options in clinical trials.
- | HRS-5965 / Jiangsu Hengrui Pharma
Journal, Monotherapy: Efficacy and safety of HRS-5965 monotherapy in complement inhibitor-na (Pubmed Central) - Aug 26, 2025
The most common treatment-related adverse events were mild lab abnormalities, including increased alkaline phosphatase and alanine aminotransferase. In conclusion, HRS-5965 monotherapy at either 50 or 75?mg BID resulted in substantial Hb improvements and reduced haemolysis with an acceptable safety profile, suggesting its potential as a promising oral therapy for complement inhibitor-na
- | ketamine / Generic mfg., AiTan (rivoceranib) / HLB Bio Group
Journal: Inhibition Mechanism of Ketamine-Apatinib by CYP2C9 and 3A4: A Prediction of Possible Drug-Drug Interaction. (Pubmed Central) - Aug 26, 2025
In conclusion, HRS-5965 monotherapy at either 50 or 75?mg BID resulted in substantial Hb improvements and reduced haemolysis with an acceptable safety profile, suggesting its potential as a promising oral therapy for complement inhibitor-na Molecular docking revealed apatinib's stronger binding affinity (-10.4
- || zeprumetostat (SHR-2554) / Treeline Biosci, fluconazole oral / Generic mfg.
P1 data, PK/PD data, Journal: Pharmacokinetic interaction between SHR2554 and fluconazole: A single-center, open-label and one-sequence crossover phase I trial in healthy Chinese subjects. (Pubmed Central) - Aug 25, 2025
Safety evaluations indicated that the observed treatment-emergent adverse events were mild and transient. These findings underline the necessity of caution when co-administered SHR2554 with moderate CYP3A4 inhibitors in clinical settings, providing crucial insights for optimizing future clinical trials.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer. (Pubmed Central) - Aug 25, 2025
We explored the feasibility and efficacy of sintilimab plus two-drug chemotherapy (S-1 plus nab-paclitaxel) and apatinib as conversion therapy in patients with stage IV gastric cancer in China...The safety profile was manageable. Sintilimab plus chemotherapy and apatinib followed by conversional resection may be a new feasible and safe option for initially unresectable gastric cancer, potentially leading to long-term survival or even cure.
- | Journal: Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy. (Pubmed Central) - Aug 25, 2025
Genomic and immune characteristics were analyzed to understand the underlying disease mechanisms. In conclusion, integrated therapy (immunotherapy, chemotherapy, local radiotherapy, and anti-angiogenic therapy) may be the ideal treatment approach for patients with GSCC with multiple metastases; however, prospective studies are needed to verify its efficacy.
- AiTan (rivoceranib) / HLB Bio Group
Apatinib versus Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Updated Overall Survival Results from the Phase 3 REALITY trial () - Aug 25, 2025 - Abstract #ATA2025ATA_615;
During long-term follow-up, apatinib showed clinically meaningful improvement in OS for patients with progressive locally advanced or metastatic, RAIR-DTC. The absence of statistical significance in OS difference between groups is likely attributed to the small sample size and treatment crossover.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Journal: Revolutionizing HER2-Positive Breast Cancer Treatment: Insights from the 47th San Antonio Breast Cancer Symposium on Trastuzumab Deruxtecan. (Pubmed Central) - Aug 24, 2025
The editorial also highlights the importance of real-world applications, ongoing research into biomarkers, and the potential of combination therapies, such as T-DXd with pyrotinib. The findings suggest that T-DXd not only extends survival but also enhances health-related quality of life for patients, promising a transformative shift in treatment paradigms for HER2-positive breast cancer.
- | SHR-1802 / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment change, Trial termination: A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - Aug 23, 2025
P2, N=25, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
The findings suggest that T-DXd not only extends survival but also enhances health-related quality of life for patients, promising a transformative shift in treatment paradigms for HER2-positive breast cancer. N=124 --> 25 | Recruiting --> Terminated; Adjustment of R&D strategy
- | Trial completion date, Trial primary completion date: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Aug 22, 2025
P2, N=716, Recruiting, Sponsor: Fudan University
N=124 --> 25 | Recruiting --> Terminated; Adjustment of R&D strategy Trial completion date: Sep 2025 --> Sep 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen (clinicaltrials.gov) - Aug 22, 2025
P2, N=34, Not yet recruiting, Sponsor: The First Affiliated Hospital of Xiamen University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study (clinicaltrials.gov) - Aug 22, 2025
P2, N=70, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer (clinicaltrials.gov) - Aug 22, 2025
P2, N=37, Recruiting, Sponsor: Yongjun Chen